Abiomed acquires ECMO developer
Click Here to Manage Email Alerts
Abiomed announced it has acquired Breethe, developer of an extracorporeal membrane oxygenation system, in an effort to better support patients with cardiogenic shock or other conditions which produce insufficient oxygen to the lungs.
According to a press release from Abiomed, which makes and markets mechanical circulatory support systems under the Impella brand name, patients who require extracorporeal membrane oxygenation include those experiencing cardiogenic shock or respiratory failure due to conditions such as acute respiratory distress syndrome, H1N1, SARS and COVID-19.
Breethe’s product is an external respiratory assistance device that eliminates the need for oxygen tanks by taking venous blood from the patient, removing carbon dioxide, adding oxygen and then sending the oxygenated blood back to the patient, Abiomed stated in the release. Extracorporeal membrane oxygenation perfuses the end organs but does not unload the left ventricle, which increases the oxygen demand of the myocardium, according to the release.
“This acquisition aligns with our principles of leading in technology and innovation, putting patients first and striving to continually improve outcomes,” Michael R. Minogue, chairman, president and CEO of Abiomed, said in the release. “Physicians have asked Abiomed to bring this technology into our portfolio because of our ability to support patients, teach best practices and collect critical data for research. This ECMO technology will allow us to treat cardiogenic shock patients who are already being supported with Impella, add pediatric offerings and treat a new patient population with respiratory failure.”
Disclosures: Minogue is an employee of Abiomed.
Collapse
Click Here to Manage Email Alerts